Eli Lilly & Co. vs. NewAmsterdam Pharma Company N.V. Ordinary Shares
LLY
Eli Lilly & Co.
$1183.46 +0.13%
VS NAMSNewAmsterdam Pharma Company N.V. Ordinary Shares
$22.58 -0.70%
Eli Lilly & Co. (LLY) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| LLY | NAMS | |
|---|---|---|
| Market Cap | $1.05 trillion | $2.70 billion |
| Revenue (TTM) | $79.67 billion | $7.12 million |
| Net Income (TTM) | $26.71 billion | $-259,504,000 |
LLY leads on 3 of 3 size & scale factors.
Valuation
| LLY | NAMS | |
|---|---|---|
| P/E Ratio | 39.73 | — |
| Price / Book | 31.14 | 4.27 |
| Price / Sales | 13.24 | 379.04 |
LLY and NAMS split the valuation factors evenly.
Profitability
| LLY | NAMS | |
|---|---|---|
| Net Margin | 33.53% | -3644.21% |
| Return on Equity | 78.84% | -41.10% |
LLY leads on 2 of 2 profitability factors.
Dividend
| LLY | NAMS | |
|---|---|---|
| Dividend Yield | 0.58% | — |
| Payout Ratio | 23.23 | — |
LLY and NAMS split the dividend factors evenly.
Risk & Sentiment
| LLY | NAMS | |
|---|---|---|
| Short Interest | 1.29% | 0.01% |
NAMS leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, NAMS overview, NAMS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.